Actinium-225

Actinium-225
Dr Andrew R. Burgoyne · CC BY-SA 4.0 · source
Name	Actinium-225
Mass number	225
Protons	89
Neutrons	136
Half life	9.920 days
Decay modes	Alpha decay; beta decay (minor)
Decay products	Francium-221; Thorium-225; others in decay chain
Parent isotopes	Radium-225; Thorium-229 (via decay chains)

Actinium-225 Actinium-225 is a radioactive isotope used primarily in targeted alpha therapy and nuclear medicine. It is notable for a relatively short half-life that balances radiobiological potency with logistical constraints, and for its position in decay chains connected to thorium and radium isotopes. Research and production involve collaborations among national laboratories, pharmaceutical companies, and academic institutions.

Introduction

Actinium-225 appears in decay sequences linked to Thorium-229, Radium-225, and longer-lived progenitors such as Uranium-233 in some fuel cycles. Interest from the U.S. Department of Energy, European Commission, and several biotechnology firms has driven efforts to secure supplies for clinical trials and commercial therapies. The isotope features in discussions at conferences hosted by organizations like the International Atomic Energy Agency and has been the subject of reports by agencies such as the National Academies of Sciences, Engineering, and Medicine.

Properties and Nuclear Characteristics

Actinium-225 decays predominantly by alpha emission, producing daughter nuclides including Francium-221 and Bismuth-213 through a short decay chain that delivers multiple high-linear energy transfer events. Its half-life of approximately 10 days places it between very short-lived isotopes like Bismuth-213 and longer-lived actinides such as Actinium-227, affecting logistics for distribution from production sites such as the Oak Ridge National Laboratory and the European Organization for Nuclear Research. Nuclear data for mass excess, Q-values, and branching ratios are compiled in databases maintained by institutions including the National Nuclear Data Center and the International Atomic Energy Agency.

Production and Supply

Primary routes to obtain Actinium-225 include decay harvesting from parent isotopes like Thorium-229 inventories, radiochemical separation following irradiation of Radium-226 or Actinium-226 targets in research reactors such as the High Flux Isotope Reactor at Oak Ridge National Laboratory, and accelerator-driven spallation or proton-induced reactions at facilities like the Brookhaven National Laboratory and Los Alamos National Laboratory. Commercialization pathways have involved partnerships with biotechnology companies, national laboratories, and suppliers associated with the U.S. Department of Energy and the European Commission's consortiums. Supply-chain concerns have prompted strategic initiatives by agencies including the U.S. Food and Drug Administration and procurement programs tied to hospital networks and pharmaceutical manufacturers.

Medical and Therapeutic Applications

Actinium-225 is exploited in targeted alpha therapy (TAT) for oncology, conjugated to monoclonal antibodies and small molecules developed by firms and academic groups affiliated with centers such as Johns Hopkins University, Memorial Sloan Kettering Cancer Center, and Mayo Clinic. Clinical trials sponsored or coordinated by entities like the National Cancer Institute and commercial developers evaluate Ac-225-labeled agents against malignancies including prostate cancer, hematologic neoplasms, and solid tumors investigated in multicenter studies across institutions such as Dana-Farber Cancer Institute and MD Anderson Cancer Center. The isotope's decay yields therapeutic payloads compared in literature with alternatives like Lutetium-177 and Thorium-227, and regulatory oversight involves submissions to agencies like the European Medicines Agency and the U.S. Food and Drug Administration.

Chemistry and Compounds

Chemistry of actinium isotopes is studied within inorganic and coordination chemistry programs at universities such as University of California, Berkeley, Massachusetts Institute of Technology, and Université Paris-Saclay. Actinium(III) mimics lanthanide(III) behavior, and chelation strategies use ligands developed in collaboration with groups at institutions like Karolinska Institutet and companies producing chelators for radiopharmaceuticals. Separation chemistry leverages expertise from national labs including Argonne National Laboratory and Los Alamos National Laboratory to purify milligram-to-microcurie quantities for radiolabeling. Investigations reference contrast with chemistry of Radium-226 and Thorium-229, and exploit techniques from analytical centers such as the National Institute of Standards and Technology.

Safety, Handling, and Regulation

Handling Actinium-225 requires radiation protection protocols aligned with guidance from the International Atomic Energy Agency, Nuclear Regulatory Commission, and national health agencies like the Centers for Disease Control and Prevention. Facilities performing radiolabeling and clinical dispensing operate under licenses held by hospitals and research reactors, with waste management coordinated with organizations including the U.S. Department of Energy and regional regulatory bodies. Medical use is governed by good manufacturing practice accreditation systems and oversight similar to that imposed by the European Medicines Agency and national competent authorities for radiopharmaceuticals. Emergency preparedness and transport follow regulations from entities like the International Air Transport Association and national transport safety administrations.

History and Research Developments

Historical and contemporary research on Actinium-225 spans investigations at institutions such as Lawrence Berkeley National Laboratory in early actinide chemistry and modern clinical translation led by collaborations among National Cancer Institute, university hospitals, and biotech firms. Key developments include advances in production at reactors and accelerators at Oak Ridge National Laboratory and Brookhaven National Laboratory, clinical trial milestones reported by centers like Memorial Sloan Kettering Cancer Center, and policy responses by agencies such as the U.S. Department of Energy to supply constraints. Ongoing research continues in consortiums and funded programs involving the European Commission, national research councils, and philanthropic foundations supporting translational radiopharmaceutical science.

Category:Actinium isotopes